Hypoxia increases the metastatic ability of breast cancer cells via upregulation of CXCR4

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Cronin, Patricia A ^a   Wang, Jiang H ^a   Redmond, H Paul ^a  

^a Department of Medicine National University of Ireland Cork   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MAB004; MONOCLONAL ANTIBODY MAB172; PLERIXAFOR; STROMAL CELL DERIVED FACTOR 1ALPHA; UNCLASSIFIED DRUG; CXCL12 PROTEIN, HUMAN; CXCL12 PROTEIN, MOUSE; CXCR4 PROTEIN, HUMAN; HETEROCYCLIC COMPOUND; RECOMBINANT PROTEIN; STROMAL CELL DERIVED FACTOR 1;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL HYPOXIA; CELL INVASION; CELL MIGRATION; CELL STRAIN MCF 7; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; METASTASIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; UPREGULATION; ANIMAL; BREAST TUMOR; CANCER INVASION; CELL MEMBRANE; CHEMOTAXIS; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; METABOLISM; PATHOLOGY; TIME; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL HYPOXIA; CELL LINE, TUMOR; CELL MEMBRANE; CHEMOKINE CXCL12; CHEMOTAXIS; FEMALE; FLOW CYTOMETRY; HETEROCYCLIC COMPOUNDS; HUMANS; MICE; NEOPLASM INVASIVENESS; RECEPTORS, CXCR4; RECOMBINANT PROTEINS; TIME FACTORS; UP-REGULATION;

EID: 77952455508     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-225     Document Type: Article

References (51)

1. McPherson K, Steel CM, Dixon JM. ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ 2000, 321:624-8. 10.1136/bmj.321.7261.624, 1118507, 10977847.
2. Nicolson GL. Paracrine and autocrine growth mechanisms in tumor metastasis to specific sites with particular emphasis on brain and lung metastasis. Cancer Metastasis Rev 1993, 12:325-43. 10.1007/BF00665961, 8281616.
3. Youngs SJ, Ali SA, Taub DD, Rees RC. Chemokines induce migrational responses in human breast carcinoma cell lines. Int J Cancer 1997, 71:257-66. 10.1002/(SICI)1097-0215(19970410)71:2<257::AID-IJC22>3.0.CO;2-D, 9139852.
4. Verbeek BS, Adriaansen-Slot SS, Vroom TM, Beckers T, Rijksen G. Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts. FEBS Lett 1998, 425:145-50. 10.1016/S0014-5793(98)00224-5, 9541025.
5. Kim H, Muller WJ. The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis. Exp Cell Res 1999, 253:78-87. 10.1006/excr.1999.4706, 10579913.
6. Hilakivi-Clarke L. Estrogens, BRCA1, and breast cancer. Cancer Res 2000, 60:4993-5001.
7. Hyder SM, Chiappetta C, Stancel GM. Pharmacological and endogenous progestins induce vascular endothelial growth factor expression in human breast cancer cells. Int J Cancer 2001, 92:469-73. 10.1002/ijc.1236, 11304678.
8. McEarchern JA, Kobie JJ, Mack V, Wu RS, Meade-Tollin L, Arteaga CL, Dumont N, Besselsen D, Seftor E, Hendrix MJ, Katsanis E, Akporiaye ET. Invasion and metastasis of a mammary tumor involves TGF-beta signaling. Int J Cancer 2001, 91:76-82. 10.1002/1097-0215(20010101)91:1<76::AID-IJC1012>3.0.CO;2-8, 11149423.
9. Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verástegui E, Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-6. 10.1038/35065016, 11242036.
10. Lundgren K, Holm C, Landberg G. Hypoxia and breast cancer: prognostic and therapeutic implications. Cell Mol Life Sci 2007, 64:3233-47. 10.1007/s00018-007-7390-6, 17957335.
11. Brizel DM, Rosner GL, Prosnitz LR, Dewhirst MW. Patterns and variability of tumor oxygenation in human soft tissue sarcomas, cervical carcinomas, and lymph node metastases. Int J Radiat Oncol Biol Phys 1995, 32:1121-5.
12. Vaupel P, Hockel M, Mayer A. Detection and characterization of tumor hypoxia using pO2 histography. Antioxid Redox Signal 2007, 9:1221-35. 10.1089/ars.2007.1628, 17536958.
13. Vaupel P, Okunieff P, Neuringer LJ. Blood flow, tissue oxygenation, pH distribution, and energy metabolism of murine mammary adenocarcinomas during growth. Adv Exp Med Biol 1989, 248:835-45.
14. Vaupel P, Schlenger K, Knoop C, Hockel M. Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res 1991, 51:3316-22.
15. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002, 2:38-47. 10.1038/nrc704, 11902584.
16. Smith TG, Robbins PA, Ratcliffe PJ. The human side of hypoxia-inducible factor. Br J Haematol 2008, 141:325-34. 2408651, 18410568.
17. Semenza GL. Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol Med 2001, 7:345-50. 10.1016/S1471-4914(01)02090-1, 11516994.
18. Bos R, Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ, Wall E. Levels of hypoxia-inducible factor-1α independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 2003, 97:1573-1581. 10.1002/cncr.11246, 12627523.
19. Gruber G, Greiner RH, Hlushchuk R, Aebersold DM, Altermatt HJ, Berclaz G, Djonov V. Hypoxia-inducible factor 1 alpha in high-risk breast cancer: An independent prognostic parameter?. Breast Cancer Res 2004, 6:R191-R198. 10.1186/bcr775, 400672, 15084243.
20. Vleugel MM, Greijer AE, Shvarts A, Groep P, van Berkel M, Aarbodem Y, van Tinteren H, Harris AL, van Diest PJ, Wall E. Differential prognostic impact of hypoxia induced and diffuse HIF-1α expression in invasive breast cancer. J Clin Pathol 2005, 58:172-177. 10.1136/jcp.2004.019885, 1770566, 15677538.
21. Trastour C, Benizri E, Ettore F, Ramaioli A, Chamorey E, Pouysségur J, Berra E. HIF-1alpha and CA IX staining in invasive breast carcinomas: Prognosis and treatment outcome. Int J Cancer 2007, 120:1451-1458. 10.1002/ijc.22436, 17245699.
22. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W. Chemokine receptor CXCR4 down-regulated by von Hippel- Lindau tumour suppressor pVHL. Nature 2003, 425:307-311. 10.1038/nature01874, 13679920.
23. Zagzag D, Krishnamachary B, Yee H, Okuyama H, Chiriboga L, Ali MA, Melamed J, Semenza GL. Stromal cell-derived factor-1α and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res 2005, 65:6178-6188. 10.1158/0008-5472.CAN-04-4406, 16024619.
24. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001, 410:37-40. 10.1038/35065000, 11242034.
25. Fresno Vara J, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004, 30:193-204. 10.1016/j.ctrv.2003.07.007, 15023437.
26. Zhou Y, Larsen P, Hao C, Yong V. CXCR4 is a major chemokine receptor on glioma cells and mediates their survival. J Biol Chem 2002, 277:19481-19487.
27. Vlahakis S, Villasis-Keever A, Gomez T, Vanegas M, Vlahakis N, Paya C. G protein-coupled chemokine receptors induce both survival and apoptotic signaling pathways. J Immunol 2002, 169:5546-5554.
28. Vila-Coro A, Rodriguez-Frade J, Martin De Ana A, Moreno-Ortiz M, Martinez-A C, Mellado M. The chemokine SDF-1alpha triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway. Fed Am Soc Exp Biol J 1999, 13:1699-1710.
29. Wang JM, Deng X, Gong W, Su S. Chemokines and their role in tumor growth and metastasis. J Immunol Methods 1998, 220:1-17. 10.1016/S0022-1759(98)00128-8, 9839921.
30. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000, 12:121-127. 10.1016/S1074-7613(00)80165-X, 10714678.
31. Campbell JJ, Butcher EC. Chemokines in tissue-specific and microenvironment-specific lymphocyte homing. Curr Opin Immunol 2000, 12:336-341. 10.1016/S0952-7915(00)00096-0, 10781407.
32. Morales J, Homey B, Vicari AP, Hudak S, Oldham E, Hedrick J, Orozco R, Copeland NG, Jenkins NA, McEvoy LM, Zlotnik A. CTACK, a skin-associated chemokine that preferentially attracts skin-homing memory T cells. Proc Natl Acad Sci USA 1999, 96:14470-14475. 10.1073/pnas.96.25.14470, 24460, 10588729.
33. Homey B, Wang W, Soto H, Buchanan ME, Wiesenborn A, Catron D, Müller A, McClanahan TK, Dieu-Nosjean MC, Orozco R, Ruzicka T, Lehmann P, Oldham E, Zlotnik A. Cutting edge: the orphan chemokine receptor G protein-coupled receptor-2 (GPR-2, CCR10) binds the skin-associated chemokine CCL27 (CTACK/ALP/ILC). J Immunol 2000, 164:3465-3470.
34. Peled A, Petit I, Kollet O, Magid M, Ponomaryov T, Byk T, Nagler A, Ben-Hur H, Many A, Shultz L, Lider O, Alon R, Zipori D, Lapidot T. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 1999, 283:845-848. 10.1126/science.283.5403.845, 9933168.
35. Förster R, Schubel A, Breitfeld D, Kremmer E, Renner-Müller I, Wolf E, Lipp M. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 1999, 99:23-33. 10.1016/S0092-8674(00)80059-8, 10520991.
36. Hedrick JA, Zlotnik A. Identification and characterization of a novel beta chemokine containing six conserved cysteines. J Immunol 1997, 159:1589-1593.
37. Campbell JJ, Hedrick J, Zlotnik A, Siani MA, Thompson DA, Butcher EC. Chemokines and the arrest of lymphocytes rolling under flow conditions. Science 1998, 279:381-384. 10.1126/science.279.5349.381, 9430588.
38. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889, 133:571-573.
39. Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, Chen E, Gottschalk AR, Ryan HE, Johnson RS, Jefferson AB, Stokoe D, Giaccia AJ. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 2000, 14:391-396. 316386, 10691731.
40. Blagosklonny MV, An WG, Romanova LY, Trepe J, Fojo T, Neckers L. p53 inhibits hypoxia-inducible factor-stimulated transcription. J Biol Chem 1998, 273:11995-11998. 10.1074/jbc.273.20.11995, 9575138.
41. Schioppa T, Uranchimeg B, Saccani A, Biswas SK, Doni A, Rapisarda A, Bernasconi S, Saccani S, Nebuloni M, Vago L, Mantovani A, Melillo G, Sica A. Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 2003, 198:1391-1402. 10.1084/jem.20030267, 2194248, 14597738.
42. Harvey JR, Mellor P, Eldaly H, Lennard TW, Kirby JA, Ali S. Inhibition of CXCR4-Mediated Breast Cancer Metastasis: A Potential Role for Heparinoids?. Clin Cancer Res 2007, 13:1562-70. 10.1158/1078-0432.CCR-06-1987, 17332302.
43. Chu QD, Panu L, Holm N, Li B, Johnson L, Zhang S. High chemokine receptor CXCR4 level in triple negative breast cancer specimens predicts poor clinical outcome. J Surg Res 2010, 159:689-95. 10.1016/j.jss.2008.09.020, 19500800.
44. Andre F, Xia W, Conforti R, Wei Y, Boulet T, Tomasic G, Spielmann M, Zoubir M, Berrada N, Arriagada R, Hortobagyi GN, Hung MC, Pusztai L, Delaloge S, Michiels S, Cristofanilli M. CXCR4 expression in early breast cancer and risk of distant recurrence. Oncologist 2009, 14:1182-8. 10.1634/theoncologist.2009-0161, 19939894.
45. Holm NT, Byrnes K, Li BD, Turnage RH, Abreo F, Mathis JM, Chu QD. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence. J Surg Res 2007, 141:53-9. 10.1016/j.jss.2007.03.015, 17574038.
46. Andre F, Cabioglu N, Assi H, Sabourin JC, Delaloge S, Sahin A, Broglio K, Spano JP, Combadiere C, Bucana C, Soria JC, Cristofanilli M. Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol 2006, 17:945-51. 10.1093/annonc/mdl053, 16627550.
47. Cabioglu N, Sahin A, Doucet M, Yavuz E, Igci A, O Yildirim E, Aktas E, Bilgic S, Kiran B, Deniz G, Price JE. Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow. Clin Exp Metastasis 2005, 22:39-46. 10.1007/s10585-005-3222-y, 16132577.
48. Coffey JC, Wang JH, Smith MJF, Bouchier-Hayes D, Cotter TG, Redmond HP. Excisional surgery for cancer cure: Therapy at a cost. Lancet Oncol 2003, 4:760-768. 10.1016/S1470-2045(03)01282-8, 14662433.
49. Galán M, Viñolas N, Colomer D, Soler G, Muñoz M, Longarón R, Ventura PJ, Gascón P, Estapé J. Detection of occult breast cancer cells by amplification of CK19 mRNA by reverse transcriptase-polymerase chain reaction: role of surgical manipulation. Anticancer Res 2002, 22:2877-84.
50. Topal B, Aerts JL, Roskams T, Fieuws S, Van Pelt J, Vandekerckhove P, Penninckx F. Cancer cell dissemination during curative surgery for colorectal liver metastases. Eur J Surg Oncol 2005, 31:506-11. 10.1016/j.ejso.2005.01.007, 15922887.
51. DiPersio JF, Uy GL, Yasothan U, Kirkpatrick. Plerixafor. Nat Rev Drug Discov 2009, 8:105-6. 10.1038/nrd2819, 19180104.